Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Jun 5.

Published in final edited form as: Exp Lung Res. 2012 Apr;38(3):124–134. doi: 10.3109/01902148.2012.658148

F4 TERC deficient, F6 TERT deficient, and wild type control mice had similar levels of lung fibrosis following intratracheal bleomycin. A–F) Trichrome blue stained lung sections from A,D) F4 TERC deficient, B,E) F6 TERT deficient, and C,F) wild type (WT) control mice. Magnification: A–C x40; D–F x200. G) Semiquantitative scoring of lung fibrosis from 8–10 week old F4 TERC deficient (F4 TERC −/−), F6 TERT deficient (F6 TERT −/−), and wild type (WT) control mice at 3 weeks following 0.04 units of bleomycin. N=11 for F4 TERC−/−, 11 for F6 TERT −/−, and 13 for WT. Experiment survival was 11/13 for F4 TERC−/−, 11/13 for F6 TERT −/−, and 13/15 for WT. H) Semiquantitative scoring of lung fibrosis from 8–10 week old F4 TERC −/−, F6 TERT −/−, and WT control mice at 3 weeks following 0.08 units of bleomycin. N=5 for F4 TERC −/−, 9 for F6 TERT −/−, and 7 for WT. Experiment survival was 5/8 for F4 TERC −/−, 9/12 for F6 TERT −/−, and 7/10 for WT. I) Semiquantitative scoring of lung fibrosis and J) total lung collagen content as assessed by a microplate hydroxyproline assay from 8–12 month old F4 TERC −/−, F6 TERT −/−, and WT control mice at 3 weeks following 0.04 units of bleomycin (bleo) or saline. N=9 for F4 TERC −/− saline treated, F6 TERT −/− saline treated, WT saline treated, and F4 TERC −/− bleomycin treated; 12 for F6 TERT −/− bleomycin treated; and 10 for WT bleomycin treated. Experiment survival post bleomycin was 9/10 for F4 TERC −/−, 12/13 for F6 TERT −/−, and 10/10 for WT. For collagen data in J, p<0.05 between individual genotype columns for saline versus bleo. K) Semiquantitative scoring of lung fibrosis from 8–10 week old F4 TERT −/− and WT controls at 2 weeks following 8 biweekly repetitive doses of 0.04 units of intratracheal bleomycin. N = 12 for F4 TERT −/− and 9 for WT. Experiment survival was 12/14 for F4 TERT −/− and 9/11 for WT.

F4 TERC deficient, F6 TERT deficient, and wild type control mice had similar levels of lung fibrosis following intratracheal bleomycin. A–F) Trichrome blue stained lung sections from A,D) F4 TERC deficient, B,E) F6 TERT deficient, and C,F) wild type (WT) control mice. Magnification: A–C x40; D–F x200. G) Semiquantitative scoring of lung fibrosis from 8–10 week old F4 TERC deficient (F4 TERC −/−), F6 TERT deficient (F6 TERT −/−), and wild type (WT) control mice at 3 weeks following 0.04 units of bleomycin. N=11 for F4 TERC−/−, 11 for F6 TERT −/−, and 13 for WT. Experiment survival was 11/13 for F4 TERC−/−, 11/13 for F6 TERT −/−, and 13/15 for WT. H) Semiquantitative scoring of lung fibrosis from 8–10 week old F4 TERC −/−, F6 TERT −/−, and WT control mice at 3 weeks following 0.08 units of bleomycin. N=5 for F4 TERC −/−, 9 for F6 TERT −/−, and 7 for WT. Experiment survival was 5/8 for F4 TERC −/−, 9/12 for F6 TERT −/−, and 7/10 for WT. I) Semiquantitative scoring of lung fibrosis and J) total lung collagen content as assessed by a microplate hydroxyproline assay from 8–12 month old F4 TERC −/−, F6 TERT −/−, and WT control mice at 3 weeks following 0.04 units of bleomycin (bleo) or saline. N=9 for F4 TERC −/− saline treated, F6 TERT −/− saline treated, WT saline treated, and F4 TERC −/− bleomycin treated; 12 for F6 TERT −/− bleomycin treated; and 10 for WT bleomycin treated. Experiment survival post bleomycin was 9/10 for F4 TERC −/−, 12/13 for F6 TERT −/−, and 10/10 for WT. For collagen data in J, p<0.05 between individual genotype columns for saline versus bleo. K) Semiquantitative scoring of lung fibrosis from 8–10 week old F4 TERT −/− and WT controls at 2 weeks following 8 biweekly repetitive doses of 0.04 units of intratracheal bleomycin. N = 12 for F4 TERT −/− and 9 for WT. Experiment survival was 12/14 for F4 TERT −/− and 9/11 for WT.